Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses

Metformin has been under basic and clinical study as an oncological repurposing pharmacological agent for several years, stemming from observational studies which consistently evidenced that subjects who were treated with metformin had a reduced risk for development of cancer throughout their lives,...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrios-Bernal, Pedro, Zatarain-Barrón, Zyanya Lucia, Hernández-Pedro, Norma, Orozco-Morales, Mario, Olivera-Ramírez, Alejandra, Ávila-Moreno, Federico, Colín-González, Ana Laura, Cardona, Andrés F., Rosell, Rafael, Arrieta, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318003/
https://www.ncbi.nlm.nih.gov/pubmed/35890085
http://dx.doi.org/10.3390/ph15070786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318003/
https://www.ncbi.nlm.nih.gov/pubmed/35890085
http://dx.doi.org/10.3390/ph15070786

Ejemplares similares